In preclinical animal models, the host response to 5-FU cancer treatment and anti-PD1 immunotherapy was particularly improved by administrating C.B. Our study uncovers C.B as a potential anti-cancer agent regulating important aspects of drug resistance and immune surveillance escape during tumor treatment and provides insight into potential cancer treatment strategies. This evidence concerns the gene PDCD1 and cancer.